Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Biomedical Warming and Thawing Devices Market Size & Share 2026-2035
Report ID: GMI2912
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Biomedical Warming and Thawing Devices Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Biomedical Warming and Thawing Devices Market Size
The biomedical warming and thawing devices market was valued at USD 298.1 million in 2025, is projected to reach USD 323.3 million in 2026, is expected to grow at an 8.9% CAGR (2026–2035), and is projected to reach USD 692.9 million by 2035.
Biomedical Warming and Thawing Devices Market Key Takeaways
Market Leader: Thermo Fisher Scientific led with over 15.5% market share in 2025.
Leading Players: Top 5 players in this market include Thermo Fisher Scientific, Cytiva, Sartorius, Helmer Scientific, Barkey GmbH, which collectively held a market share of 52% in 2025.
The market is moving beyond conventional thermal preparation equipment toward validated platforms that protect sample integrity, document temperature transitions, and fit controlled clinical or manufacturing workflows. Blood-component handling remains the broadest installed-base opportunity, while fertility care and advanced biologics are increasing the strategic value of application-specific, automated systems.
GMI Analyst View
Based on our engagements with blood bank administrators, clinical procurement managers, and biomedical device manufacturers across multiple geographies, the biomedical warming and thawing devices market generated revenue of USD 274.3 million in 2024. Our research conversations confirm that procurement decisions are shifting decisively toward dry-heat and automated platforms that reduce cross-contamination risk and support electronic data-logging requirements under facility quality systems - a preference shift that is visibly reshaping product development priorities and distributor inventory positioning across leading manufacturers globally.
Biomedical Warming and Thawing Devices Market Trends, Growth Drivers & GMI Forecast Outlook
Demand is being broadened by transfusion services, frozen embryo transfer programs, and commercial cell and gene therapy workflows. The forecast depends on whether providers can convert rising biological-material volumes into qualified, repeatable thermal processes while managing regulatory review, infrastructure, and compatibility constraints.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Blood banking gives the market a broad, recurring equipment base because plasma, cryoprecipitate, and red-cell workflows require controlled preparation before release or administration. Growth in formal collection systems is especially meaningful when it is paired with quality-management investment, since that combination supports replacement of water-bath processes with dry-heat, agitation-based, and electronically documented alternatives. The continued expansion of organized blood collection programs and broader adoption of voluntary donation practices indicate the ongoing formalization of collection and processing networks across major healthcare markets [1]World Health Organization. "Blood Safety and Availability." who.int.
Frozen embryo transfer is reshaping equipment requirements inside IVF laboratories. Clinics using vitrification-based pathways need warming stations that deliver protocol-specific transitions without introducing thermal shock at a critical point in the treatment process. In the UK, the frozen embryo transfer share of IVF cycles rose from 24% in 2014 to 48% in 2024, while embryo-freezing cycles increased from approximately 1,900 to more than 10,450 over the same period [2]Human Fertilisation and Embryology Authority. "Fertility Treatment 2024: Trends and Figures." hfea.gov.uk. That clinical shift supports multi-workstation demand as fertility networks expand beyond their established metropolitan bases.
Cell and gene therapy introduces a more qualification-intensive source of demand. Cryopreserved cellular products must be thawed through a controlled workflow that can be aligned with bag geometry, temperature profiles, process records, and site-specific validation. Eight first-ever global CGT product approvals were recorded in 2025, reinforcing the commercial progression of treatment pathways that require qualified preparation at manufacturing and care-delivery sites [4]International Society for Cell & Gene Therapy. "Fifth Global Regulatory Report: 2025." isctglobal.org. This requirement favors suppliers able to combine thermal control with documentation, closed-system compatibility, and implementation support.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Regulatory burden affects both product launches and customer adoption. Manufacturers must establish that a device is safe and fit for its intended clinical use, while hospitals, blood establishments, and pharmaceutical sites often conduct their own qualification work before placing equipment into service. This creates a longer route to revenue for specialized platforms and can favor established suppliers with existing regulatory documentation, service capability, and installed-base relationships.
Infrastructure gaps also limit how quickly rising blood collection volumes convert into equipment placements. Where blood systems remain concentrated in collection and storage rather than advanced component processing, the need for dedicated plasma thawing, validated temperature documentation, and automated handling is comparatively limited. The resulting demand curve is tied to capital investment in cold chains, workforce capability, laboratory procedures, and quality systems rather than donation growth alone.
Compatibility remains an operational constraint in higher-specification applications. Plasma bags, cellular-therapy cryobags, and reproductive specimen devices have different dimensions, material properties, and handling requirements. Customers may therefore prioritize platforms already validated for their workflows, extending evaluation cycles and limiting the practical interchangeability of equipment.
GMI Analyst View
We see the market separating into two purchasing environments. Pharmaceutical and cell therapy users are increasingly selecting platforms for validation depth, data traceability, and workflow integration, whereas many blood banks remain focused on dependable, cost-conscious replacement. Suppliers that can serve both requirements without diluting application expertise will be better positioned as automation adoption progresses unevenly.
Biomedical Warming and Thawing Devices Market Segment Analysis
By Product
In the biomedical warming and thawing devices market, thawing devices generated USD 179.5 million in 2025 and are projected to reach USD 425.3 million by 2035. Their position reflects use across plasma, cellular therapy, IVF, semen, and biopharmaceutical workflows, where controlled reversal of cryopreservation is central to protecting specimen viability, potency, or sterility. The category is gaining technical depth as dry-heat and closed-system designs replace less controlled approaches in settings with higher documentation requirements.
Warming devices are projected to reach USD 267.6 million by 2035 and held a 39.8% share in 2025. This category serves a different clinical function, supporting preparation of chilled blood products and intravenous fluids before administration. Demand is supported by surgical, emergency, trauma, and critical-care use cases, where portability, response time, and compatibility with varied care environments shape product selection.
By Mode
Manual devices held a 66.0% share in 2025 and are projected to generate USD 449.8 million by 2035. Their installed base remains substantial in community blood banks, smaller hospitals, and cost-sensitive facilities because they offer accessible acquisition costs and limited software qualification requirements. Replacement demand will remain important, even as higher-complexity workflows migrate toward automation.
Automatic devices generated USD 101.3 million in 2025 and are projected to hold a 35.1% share by 2035. Their growth is linked to programmable operating cycles, closed-process handling, data logging, and remote monitoring capabilities. These attributes have particular relevance in CGT manufacturing and accredited fertility programs, where thermal performance must be substantiated within a defined operating procedure.
By Sample Type
Blood products generated USD 138.9 million in 2025 and are projected to account for a 45.7% share by 2035. Plasma thawing, cryoprecipitate preparation, and blood warming create a broad demand base across transfusion services. Although the segment faces a changing mix as reproductive and advanced-therapy applications expand, its underlying demand is reinforced by routine clinical use and established quality standards.
The ovum and embryo segment is projected to reach USD 160.7 million by 2035 and grow at a 9.5% CAGR (2026–2035). Its outlook is tied to the operational centrality of vitrification reversal in modern IVF practice. Dedicated warming platforms allow laboratories to standardize timing and handling at a sensitive stage of care, making them increasingly integral to clinics that have adopted frozen-transfer-led treatment pathways.
Semen accounted for a 10.0% share in 2025 and is projected to generate USD 65.3 million by 2035. Demand spans fertility programs, oncology-linked preservation services, and veterinary reproductive medicine. The segment requires equipment suited to precise incubation profiles, but its purchasing decisions are typically shaped by laboratory throughput and protocol consistency rather than the larger capital-equipment requirements associated with CGT workflows.
Other sample types are projected to hold a 21.7% share by 2035 and generated USD 63.8 million in 2025. This grouping includes cord blood, stem cells, and biopharmaceutical materials, making it particularly exposed to the maturation of biobanking and cellular-therapy supply chains. Demand is more fragmented than in blood products, but the applications place a premium on validated processing and sample-specific compatibility.
By End Use
Blood banks and transfusion centers generated USD 93.9 million in 2025 and are projected to hold a 30.4% share by 2035. Equipment replacement is driven by quality-system requirements, procedural validation, and the need to maintain reliable preparation capacity across plasma and blood-component workflows. This creates a comparatively predictable procurement cycle, although the segment's share moderates as higher-growth applications develop.
Hospitals are projected to reach USD 192.8 million by 2035 and grow at a 9.0% CAGR (2026–2035). Their demand spans operating rooms, emergency departments, intensive-care settings, transfusion services, and hospital pharmacies. The ability to consolidate multiple clinical warming and thawing needs within a single supplier relationship can be a meaningful purchasing consideration for larger health systems.
Research laboratories held a 21.0% share in 2025 and are projected to generate USD 151.1 million by 2035. Academic institutions, biobanks, and contract research organizations need controlled thermal equipment across cell biology, preclinical research, and sample-management workflows. Requirements vary significantly by study design and sample type, preserving a broad market for both specialist and versatile laboratory platforms.
Pharmaceutical companies are projected to account for a 12.7% share by 2035 and grow at a 9.5% CAGR (2026–2035). Their requirements are shaped by biologics manufacturing, plasma-derived product handling, and CGT drug-product preparation. This end-use category is disproportionately important for suppliers of premium systems because electronic records, qualification packages, and integration with GMP processes can carry greater weight than initial equipment price.
Other end uses generated USD 23.8 million in 2025 and are projected to grow at a 7.8% CAGR (2026–2035). Veterinary care, specialty diagnostics, and service laboratories provide diversified but smaller-scale demand. Their procurement patterns are generally more mature, with decisions weighted toward dependable thermal performance, serviceability, and fit with established laboratory workflows.
GMI Analyst View
We believe product and end-use segmentation will increasingly matter more than a simple manual-versus-automatic divide. A supplier serving blood banks, IVF laboratories, and biopharmaceutical sites must address fundamentally different qualification, throughput, and service expectations. Portfolio breadth will be valuable only when it is paired with credible application-specific validation and support.
Biomedical Warming and Thawing Devices Market Regional Analysis
North America Biomedical Warming and Thawing Devices Market Analysis
The biomedical warming and thawing devices market in North America generated USD 113.2 million in 2025 and is projected to reach USD 254.7 million by 2035. The region combines established blood-processing infrastructure, active fertility-care networks, and advanced biologics activity. These conditions support a procurement environment in which compliance documentation and validated operating performance increasingly influence replacement decisions.
U.S.
The U.S. generated USD 94.3 million in 2025 and is projected to account for an 82.9% share of North American revenue by 2035. Its scale reflects extensive transfusion infrastructure and a concentration of pharmaceutical and cellular-therapy activity. Demand is increasingly differentiated between high-volume clinical blood warming and more specialized thawing systems used in validated advanced-therapy workflows.
Canada
Canada is projected to generate USD 43.5 million by 2035 and grow at an 8.7% CAGR (2026–2035). Its market is underpinned by structured blood-system procurement and gradual diversification into fertility and cellular-therapy applications. The country's institutional purchasing environment favors equipment suppliers able to provide service continuity and documented quality support.
Europe Biomedical Warming and Thawing Devices Market Analysis
Europe generated USD 80.5 million in 2025 and is projected to hold a 25.6% share by 2035. The region's market is shaped by stringent medical-device, blood-processing, and pharmaceutical manufacturing expectations. The shift toward closed, water-free processes in sterile applications is reinforcing demand for dry-heat and automated platforms with demonstrable validation capability.
Germany
Germany generated USD 14.1 million in 2025 and is projected to reach USD 31.6 million by 2035. Its demand base spans hospitals, biomedical research, and pharmaceutical manufacturing, providing several routes to market for specialized equipment. The combination of institutional scale and manufacturing activity supports demand for both routine transfusion systems and higher-specification thawing platforms.
UK
The UK is projected to generate USD 32.2 million by 2035 and held a 17.5% share of European revenue in 2025. Blood-service requirements and an active IVF sector create complementary demand channels. The country's well-established fertility treatment infrastructure and continued adoption of embryo cryopreservation support ongoing use of dedicated warming workstations and related laboratory equipment [2]Human Fertilisation and Embryology Authority. "Fertility Treatment 2024: Trends and Figures." hfea.gov.uk.
France
France generated USD 10.7 million in 2025 and is projected to grow at an 8.2% CAGR (2026–2035). Its market is characterized by established public healthcare and blood-service procurement, where replacement cycles and validated performance remain central. Growth is steady rather than disruptive, with clinical reliability and equipment qualification continuing to guide demand.
Italy
Italy is projected to hold a 10.1% share of European revenue by 2035 and generated USD 8.3 million in 2025. Hospital blood-bank operations and plasma-management procedures form the principal demand base. Procurement is expected to remain linked to qualification renewals and the replacement of equipment that no longer meets contemporary process-control requirements.
Spain
Spain held an 8.6% share of European revenue in 2025 and is projected to generate USD 15.3 million by 2035. Its demand is supported by hospital infrastructure and an active private fertility-care network. This mix creates opportunities for suppliers that can address both blood-component preparation and precise reproductive-specimen warming applications.
Netherlands
The Netherlands is projected to hold a 6.7% share of European revenue by 2035 and grow at an 8.7% CAGR (2026–2035). The country's biopharmaceutical and cell-therapy manufacturing presence supports demand for systems that can be incorporated into qualified, traceable workflows. Supplier credibility in GMP documentation and site implementation is therefore a meaningful competitive factor.
Asia Pacific Biomedical Warming and Thawing Devices Market Analysis
Asia Pacific generated USD 73.0 million in 2025 and is projected to account for a 26.5% share by 2035. Demand reflects a diverse regional mix of expanding blood-bank capacity, fertility-clinic development, and investment in pharmaceutical manufacturing. Procurement requirements vary widely, requiring suppliers to match product specification, service coverage, and qualification support to individual national markets.
China
China generated USD 23.0 million in 2025 and is projected to grow at a 10.0% CAGR (2026–2035). Blood-bank modernization, growing reproductive-care capacity, and domestic cellular-therapy development are widening the application base. The market favors suppliers that can balance clinical-quality expectations with localized commercial and technical support.
India
India is projected to generate USD 30.3 million by 2035 and grow at an 11.5% CAGR (2026–2035). The outlook reflects expanding healthcare infrastructure, wider IVF-clinic access, and a developing biologics manufacturing base. Demand growth will depend on how quickly institutions strengthen their quality systems, procurement capability, and service coverage outside major metropolitan centers.
Japan
Japan held a 22.1% share of Asia Pacific revenue in 2025 and is projected to generate USD 34.1 million by 2035. The country's mature blood-service and fertility-care infrastructure supports dependable replacement demand. Growth is more closely tied to quality upgrades and workflow modernization than to the capacity expansion seen in developing regional markets.
Australia
Australia is projected to hold a 7.1% share of Asia Pacific revenue by 2035 and generated USD 6.0 million in 2025. Its market benefits from an established ART sector and organized clinical procurement. Equipment demand is supported by users that value standardized procedures, regulatory alignment, and reliable post-installation service.
South Korea
South Korea generated USD 8.1 million in 2025 and is projected to grow at a 9.5% CAGR (2026–2035). Its technologically advanced biomedical sector supports uptake of more capable automation and thermal-control systems. Activity in fertility services and regenerative medicine broadens demand beyond conventional blood-product applications.
Latin America Biomedical Warming and Thawing Devices Market Analysis
Latin America generated USD 16.4 million in 2025 and is projected to reach USD 39.3 million by 2035. Expansion of blood-bank infrastructure, urban fertility care, and regional biologics investment creates a progressive equipment opportunity. Adoption remains uneven, however, because facility capability, regulatory maturity, and capital budgets differ substantially across national markets.
Brazil
Brazil generated USD 7.5 million in 2025 and is projected to hold a 47.3% share of Latin American revenue by 2035. Its large healthcare economy and blood-processing network make it the region's principal demand center. Growing fertility and pharmaceutical activity is gradually broadening the market beyond traditional plasma thawing and blood-warming applications.
Mexico
Mexico is projected to generate USD 10.4 million by 2035 and grow at a 9.3% CAGR (2026–2035). Public hospital investment and private healthcare development support modernization across transfusion and fertility settings. Suppliers that can support equipment qualification and maintenance through dispersed institutional networks are likely to be better positioned.
Argentina
Argentina held a 13.4% share of Latin American revenue in 2025 and is projected to grow at an 8.4% CAGR (2026–2035). Its healthcare and research base supports continued replacement demand, although purchasing conditions can be affected by broader economic volatility. Clinical reliability and maintenance accessibility remain material considerations for buyers.
Middle East and Africa Biomedical Warming and Thawing Devices Market Analysis
The biomedical warming and thawing devices market in the Middle East and Africa generated USD 14.9 million in 2025 and is projected to reach USD 37.8 million by 2035. Government-led hospital expansion, fertility-care investment, and a low installed base in several markets create growth potential. The pace of adoption will remain tied to the availability of trained personnel, quality-management systems, and blood-processing infrastructure.
South Africa
South Africa generated USD 2.4 million in 2025 and is projected to reach USD 5.3 million by 2035. Its relatively developed blood-service infrastructure provides a standards-based procurement base for validated equipment. Demand is reinforced by private fertility care and laboratory activity concentrated in major urban centers.
Saudi Arabia
Saudi Arabia is projected to hold a 26.5% share of Middle East and Africa revenue by 2035 and grow at a 10.5% CAGR (2026–2035). Healthcare transformation investment is expanding specialized hospital capacity and increasing the relevance of advanced biologic treatment pathways. These conditions support demand for both conventional clinical warming systems and qualified thawing platforms.
UAE
The UAE generated USD 4.2 million in 2025 and is projected to hold a 30.9% share of Middle East and Africa revenue by 2035. Its position as a regional healthcare and fertility-treatment hub supports demand across hospitals, laboratories, and specialist clinics. Buyers are increasingly focused on certified devices that can fit internationally aligned clinical and regulatory procedures.
GMI Analyst View
We expect regional performance to be determined less by population alone than by the ability of institutions to absorb validated technology. Mature markets reward documentation, integration, and service depth, while infrastructure-building markets create demand for robust, accessible systems. Suppliers need differentiated go-to-market models rather than a uniform regional product strategy.
Biomedical Warming and Thawing Devices Market Share & Competitive Landscape
The biomedical warming and thawing devices market exhibits a moderately concentrated competitive structure, with Thermo Fisher Scientific, Cytiva, Sartorius, Barkey, and Helmer Scientific collectively accounting for approximately 52% of global market revenue in 2025. Market competition is driven by application-specific performance, regulatory compliance, validation support, workflow integration, and after-sales service capabilities. Leading suppliers benefit from strong relationships across clinical laboratories, blood banks, biopharmaceutical manufacturers, and cell and gene therapy facilities, where reliable thawing and warming processes are critical to product quality, patient safety, and operational efficiency.
Specialist suppliers remain important in blood-bank, IVF, laboratory, and regional clinical segments. Barkey, Helmer Scientific, IVF Tech, BioLife Solutions, BioCision, Eppendorf, Haier Biomedical, PHCbi, LABCOLD, BOEKEL, and Arctiko compete through application focus, installed-base familiarity, price positioning, service access, and fit with specific handling protocols. This specialization preserves competitive intensity despite the scale advantages held by broader life-science and bioprocessing suppliers.
Recent Industry Developments
In October 2025, Peli BioThermal announced the acquisition of BioLife Solutions' Evo cryogenic portfolio, including cryogenic shippers and the evoIS technology platform for cell and gene therapy transport [6]Peli BioThermal. "Peli BioThermal Announces Acquisition to Expand Cold Chain Logistics Solutions and Advance Cryogenic Cell and Gene Therapy Transport." pelibiothermal.com. The transaction highlights ongoing consolidation across the CGT cold-chain ecosystem, where logistics, sample integrity, and validated downstream handling are increasingly interconnected.
In April 2026, MEQU announced FDA clearance for its °M Station, enabling AC-powered hospital blood and IV-fluid warming to connect with the battery-powered °M Warmer used in prehospital and transport settings [7]°MEQU. "°MEQU Eliminates a Critical Break in Trauma Care with FDA Clearance of °M Station." mequ.dk. The development reflects continued interest in warming systems that can maintain clinical continuity across emergency, transport, and hospital care settings.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →